Haloperidol mechanism of action

Riluzole preferentially blocks TTX -sensitive sodium channels , which are associated with damaged neurons . [17] [18] Riluzole has also been reported to directly inhibit the kainate and NMDA receptors . [19] However, the action of riluzole on glutamate receptors has been controversial, as no binding of the drug to any known sites has been shown for them. [20] [21] In addition, as its antiglutamatergic action is still detectable in the presence of sodium channel blockers, it is also uncertain whether or not it acts via this way. Rather, its ability to stimulate glutamate uptake seems to mediate many of its effects. [22] [23] In addition to its role in accelerating glutamate clearance from the synapse, riluzole may also prevent glutamate release from presynaptic terminals. [24] These effects combined could significantly reduce glutamate signaling and cause indirect antagonism without acting at glutamate receptors themselves.

The dose of Haloperidol Decanoate Injection, 50 mg per mL or Haloperidol Decanoate Injection, 100 mg per mL should be expressed in terms of its haloperidol content. The starting dose of haloperidol decanoate should be based on the patient's age, clinical history, physical condition, and response to previous antipsychotic therapy. The preferred approach to determining the minimum effective dose is to begin with lower initial doses and to adjust the dose upward as needed. For patients previously maintained on low doses of antipsychotics (. up to the equivalent of 10 mg/day oral haloperidol), it is recommended that the initial dose of haloperidol decanoate be 10 to 15 times the previous daily dose in oral haloperidol equivalents; limited clinical experience suggests that lower initial doses may be adequate.

The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.

Haloperidol mechanism of action

haloperidol mechanism of action


haloperidol mechanism of actionhaloperidol mechanism of actionhaloperidol mechanism of actionhaloperidol mechanism of actionhaloperidol mechanism of action